InChIKey	VERWOWGGCGHDQE-UHFFFAOYSA-N
Compound Name	Ceritinib
Canonical SMILES	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	23
Pfam Stratification	Cross-Family
Avg pChEMBL	6.9
Source	BindingDB;ChEMBL

DrugBank ID	DB09063
Drug Name	Ceritinib
CAS Number	1032900-25-6
Groups	approved investigational
ATC Codes	L01ED02
Description	Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that gen...

---

Categories: Anaplastic lymphoma kinase (ALK) inhibitors Antineoplastic Agents Antineoplastic and Immunomodulating Agents Bradycardia-Causing Agents Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Inhibitors Cytochrome P-450 CYP3A4 Inhibitors (weak) Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A4 Substrates (strength unknown) Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Enzyme Inhibitors Hyperglycemia-Associated Agents Kinase Inhibitor Moderate Risk QTc-Prolonging Agents Narrow Therapeutic Index Drugs P-glycoprotein substrates P-glycoprotein substrates with a Narrow Therapeutic Index Protein Kinase Inhibitors QTc Prolonging Agents ROS1 tyrosine kinase inhibitors Receptor Protein-Tyrosine Kinases, antagonists & inhibitors Sulfur Compounds Tyrosine Kinase Inhibitors

---

Cross-references: BindingDB: 50436850 ChEBI: 78432 CHEMBL2403108 ChemSpider: 29315053 Drugs Product Database (DPD): 22568 D10551 PDB: 4MK PubChem:57379345 PubChem:310264998 RxCUI: 1535457 Wikipedia: Ceritinib ZINC: ZINC000096272772